Evidence map›Paper›PMID 41866601›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Youcai Li, Fang Wu, Meijuan Zhou, Ziwei Yi, Wanmei Liang, Jing Zhang, Dong Li, Dazhou Li, Shaonan Zhong, Peng Hou and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Youcai Li *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Fang Wu *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Meijuan Zhou *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ziwei YiDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wanmei LiangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jing ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Dong LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Dazhou LiDepartment of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shaonan ZhongDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Peng HouDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jie LvDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Miao KeDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ruiyue ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shaoyu LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xinqing LinGuangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 71lu@163.com.ORCID 0000-0003-1997-5687

Funding

Guangdong Medical Science and Technology Research Funding A2023233Guangdong Medical Science and Technology Research Funding B2023128the National Natural Science Foundation of China No.82402418the Plan on Enhancing Scientific Research in GMU GMUCR2025-02016the Science and Technology Program of Guangzhou, China 2024A03J1157the Science and Technology Program of Guangzhou, China 2024A03J1160
6 · The paper itself

Abstract

purposeNodal immune flare (NIF) is an immune-related adverse event affecting lymph nodes after lung cancer immunotherapy. Differentiating NIF from lymph node metastasis using [

methodsWe retrospectively enrolled 589 lung cancer patients who received immunotherapy and subsequently underwent restaging by [

resultsNIF occurred in 37 of 589 patients (6.3%) with a median onset time of 5.0 months. A total of 279 regional lymph nodes showed increased [

conclusionAfter immunotherapy in lung cancer, [ CLINICAL

trial registrationthe Chinese Clinical Trial Registry: ChiCTR2100044944 (Registered: 1 April 2021, retrospectively registered, https://www.chictr.org.cn/showprojEN.html?proj=123995 ).

Indexed as

Fluorodeoxyglucose F18GelatinasesImmunotherapyLung NeoplasmsLymph NodesMembrane ProteinsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansLymphatic MetastasisMaleEndopeptidasesFibroblast Activation Protein AlphaFluorodeoxyglucose F18GelatinasesMembrane ProteinsSerine Endopeptidases[18F]FAPI[18F]FDGimmunotherapylymph node metastasesnodal immune flare

Identifiers

PMID41866601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.